Role of Cost-Sharing Subsidies on the Initiation of and Adherence to Tyrosine Kinase Inhibitor Therapy by Medicare Beneficiaries With Chronic Myeloid Leukemia.

Ritchie, Ellen K; Guerin, Annie; Wolff, Johannes; Joseph, George

Ritchie, Ellen K; Guerin, Annie; Wolff, Johannes; Joseph, George.

Afiliação

Ritchie EK; Ellen K. Ritchie, Cornell University and New York Presbyterian Hospital, New York, NY; Annie Guerin, Analysis Group, Inc., Montreal, Quebec, Canada; and Johannes Wolff and George Joseph, Novartis Pharmaceuticals Corp., East Hanover, NJ.
Guerin A; Ellen K. Ritchie, Cornell University and New York Presbyterian Hospital, New York, NY; Annie Guerin, Analysis Group, Inc., Montreal, Quebec, Canada; and Johannes Wolff and George Joseph, Novartis Pharmaceuticals Corp., East Hanover, NJ.
Wolff J; Ellen K. Ritchie, Cornell University and New York Presbyterian Hospital, New York, NY; Annie Guerin, Analysis Group, Inc., Montreal, Quebec, Canada; and Johannes Wolff and George Joseph, Novartis Pharmaceuticals Corp., East Hanover, NJ.
Joseph G; Ellen K. Ritchie, Cornell University and New York Presbyterian Hospital, New York, NY; Annie Guerin, Analysis Group, Inc., Montreal, Quebec, Canada; and Johannes Wolff and George Joseph, Novartis Pharmaceuticals Corp., East Hanover, NJ.

J Clin Oncol ; 35(15): 1744-1745, 2017 05 20.

Article em En | MEDLINE | ID: mdl-28524780

Assuntos

Leucemia Mielogênica Crônica BCR-ABL Positiva; Custo Compartilhado de Seguro; Humanos; Medicare; Inibidores de Proteínas Quinases; Proteínas Tirosina Quinases; Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Temas: ECOS / Aspectos_gerais / Financiamentos_gastos Bases de dados: MEDLINE Assunto principal: Leucemia Mielogênica Crônica BCR-ABL Positiva Tipo de estudo: Health_economic_evaluation Limite: Humans País/Região como assunto: America do norte Idioma: En Revista: J Clin Oncol Ano de publicação: 2017 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google